Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects
about
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis.COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.Lumiracoxib in the management of osteoarthritis and acute pain.Celecoxib for the treatment of atherosclerosis.
P2860
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@ast
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@en
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@nl
type
label
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@ast
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@en
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@nl
prefLabel
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@ast
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@en
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@nl
P2093
P2860
P356
P1476
Lumiracoxib does not affect th ...... se aspirin in healthy subjects
@en
P2093
M Guillaume
R Schmouder
P2860
P304
P356
10.1177/0091270005280377
P407
P577
2005-10-01T00:00:00Z